Table 1.
Meta-analyses on associations between H. pylori infection and MGL risk.
| Subsets | Persistent vs. negative | Eradicated vs. negative | ||||
|---|---|---|---|---|---|---|
| Study count | RR (95% CI) | p-value | Study count | RR (95% CI) | p-value | |
| Total | 8 | 1.58 (0.98–2.53) a | 0.06 | 8 | 0.79 (0.43–1.45) a | 0.44 |
| Study design | ||||||
| RCT only | 0 | N/A | N/A | 0 | N/A | N/A |
| Cohort only | 8 | 1.58 (0.98–2.53) a | 0.06 | 8 | 0.79 (0.43–1.45) a | 0.21 |
| Country | ||||||
| Japan | 1 | 0.82 (0.06–11.33) | 0.88 | 1 | 1.01 (0.14–7.10) | 0.99 |
| Korea | 7 | 1.61 (0.99–2.61) a | 0.06 | 7 | 0.78 (0.40–1.50) a | 0.45 |
| Primary disease | ||||||
| EGC or dysplasia | 1 | 3.80 (1.31–10.97) | 0.01 | 1 | 5.41 (1.72–17.01) | <0.01 |
| EGC only | 6 | 1.42 (0.79–2.57) a | 0.24 | 6 | 0.64 (0.37–1.10) a | 0.10 |
| Dysplasia only | 1 | 1.27 (0.58–2.78) | 0.55 | 1 | 0.53 (0.26–1.10) | 0.09 |
| MGL outcome | ||||||
| MGC or dysplasia | 3 | 1.93 (1.17–3.17) | 0.01 | 3 | 1.03 (0.23–4.61) a | 0.97 |
| MGC only | 5 | 1.35 (0.63–2.92) a | 0.44 | 5 | 0.71 (0.37–1.35) a | 0.29 |
| Dysplasia only | 0 | N/A | N/A | 0 | N/A | N/A |
CI, confidence interval; EGC, early gastric cancer; MGC, metachronous gastric cancer; MGL, metachronous gastric lesion; N/A, not applicable; RCT, randomized controlled trial; RR, risk ratio.
a
Random-effects model was used due to heterogeneity.